EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Toward Precision Oral Medicine in Pemphigus Vulgaris: A Conceptual AI Framework for Rituximab Response Prediction

Emily-Alice Russu iD, Radu Ilinca iD, Liliana Gabriela Popa iD, Anca Silvia Dumitriu iD, Stana Păunică iD, Călin Giurcăneanu, Cristina-Crenguța Albu iD

Pharmaceuticals · 2026-08-15 · 19 (8) · 1292

DOI: 10.3390/ph19081292 ↗

At a glance

Journal article in Pharmaceuticals, published online on 2026-08-15. Written by Emily-Alice Russu and 6 co-authors. Institution: Doctoral School, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania. 112 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background/Objectives: Rituximab has improved outcomes in pemphigus vulgaris (PV), but treatment response remains heterogeneous and no clinically validated biomarker currently supports reliable individual-level prediction. Oral lesions frequently represent the earliest manifestation of PV and contribute substantially to disease burden and longitudinal assessment. This perspective aimed to synthesize candidate biomarkers and organize them within a conceptual, task-specific artificial intelligence (AI) framework for future rituximab outcome modeling.

Methods

A structured literature search and narrative synthesis evaluated genetic and pharmacogenomic, immunological and serological, cellular, clinical, and oral phenotypic variables potentially relevant to rituximab response. Variables were considered according to biological rationale, available evidence, temporal availability, and potential use in pretreatment prognosis or post-treatment response monitoring. No patient-level dataset was analyzed, and no model was trained or validated.

Results

Candidate pharmacogenomic variables include FCGR3A rs396991, FCGR2A rs1801274, and IL6 rs1800795, although evidence derives mainly from autoimmune diseases other than PV. IL10, TNF, TNFRSF13B, and population-specific HLA variables remain exploratory. Anti-desmoglein autoantibodies, BAFF, cytokine profiles, CD19+ B-cell depletion, CD27+ memory B-cell repopulation, regulatory T-cell dynamics, natural killer cell phenotypes, and clinical and oral phenotypic variables may provide complementary information, but none currently demonstrates sufficient independent predictive validity. The proposed RTX-AI Response Framework distinguishes the Pretreatment Prediction Component from the Post-Treatment Response Monitoring Component and assigns no numerical weights, probabilities, thresholds, or treatment recommendations.

Conclusions

The framework should be interpreted exclusively as a conceptual research architecture. Prospective multicenter data collection, standardized biomarker assessment, task-specific model development, calibration, external validation, and evaluation of clinical utility are required before potential clinical implementation.

Subjects

Author keywords

artificial intelligencebiomarkerselectronic health recordsmachine learningoral phenotypepemphigus vulgarispharmacogenomicsprecision oral medicinerituximab

Authors and institutions

  • Doctoral School, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • Department of Medical Informatics and Biostatistics, Faculty of Dentistry, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • Department of Oncologic Dermatology, Elias Emergency University Hospital, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • Department of Periodontology, Faculty of Dentistry, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • Department of Genetics, Faculty of Dentistry, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.

ORCID profiles: Emily-Alice Russu, Radu Ilinca, Liliana Gabriela Popa, Anca Silvia Dumitriu, Stana Păunică, Cristina-Crenguța Albu

Cite

APA

Russu, E. A., Ilinca, R., Popa, L. G., Dumitriu, A. S., Păunică, S., Giurcăneanu, C., & Albu, C. C. (2026). Toward Precision Oral Medicine in Pemphigus Vulgaris: A Conceptual AI Framework for Rituximab Response Prediction. Pharmaceuticals, 19(8), 1292. https://doi.org/10.3390/ph19081292

Vancouver

Russu EA, Ilinca R, Popa LG, Dumitriu AS, Păunică S, Giurcăneanu C, et al. Toward Precision Oral Medicine in Pemphigus Vulgaris: A Conceptual AI Framework for Rituximab Response Prediction. Pharmaceuticals. 2026;19(8):1292. doi:10.3390/ph19081292

BibTeX
@article{Russu2026,
  author = {Russu, Emily-Alice and Ilinca, Radu and Popa, Liliana Gabriela and Dumitriu, Anca Silvia and Păunică, Stana and Giurcăneanu, Călin and Albu, Cristina-Crenguța},
  title = {Toward Precision Oral Medicine in Pemphigus Vulgaris: A Conceptual AI Framework for Rituximab Response Prediction},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {8},
  pages = {1292},
  doi = {10.3390/ph19081292}
}
Start for free →